Covaxin shows 77.8% effectiveness against symptomatic COVID-19 cases in phase-3 trials
The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases while safety analysis shows adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent feeling serious adverse events.
The efficacy data demonstrates 63.6 per cent protection against asymptomatic COVID-19, a release from the city-based vaccine maker said. Phase 3
The whole virion inactivated vaccine against SARS-CoV2, was developed inpartnership with Indian Council of Medical Research and National Institute ofVirology in Pune. Krishna Ella, Chairman and Managing Director of Bharat Biotech, said, "The successful safety and efficacy readouts of Covaxin as a result of conducting the largest ever COVID Vaccines trials in India establishes the ability of India and developing world countries to focus towards innovation and novel product development.
We are proud to state that Innovation from India will now be available to protect global populations." Director General of ICMR, Balram Bhargava said, "I am delighted to note that Covaxin developed by ICMR and BBIL under an effective public private partnership, has demonstrated an overall efficacy of 77.8 per cent in Indias largest COVID phase 3 clinical trial thus far.
Our scientists at ICMR and BBIL have worked tirelessly to deliver a truly effective vaccine of highest international standards." He further said Covaxin will not only benefit the Indian citizens but would also immensely contribute to protect the global community against the deadly SARS-CoV-2 virus.
"I am also pleased to see that Covaxin works well against all variant strains of SARS-CoV-2.
The successful development of Covaxin has consolidated the position of Indian academia and Industry in the global arena," Bhargava said.
The Phase 3 trials were conducted between November 16, 2020 and January 7, 2021 with 25,798 participants who were randomised to BBV152 or placebo groups.
The preprint data of COVAXIN efficacy has not been certified by peer-review, according to Medrxiv in which thedata was published.
AdvertisementSEE ALSO -
BharatPe’s banking licence, Digit’s funding, Mswipe’s new CEO and more -- mega deals and launches in India’s fintech space
Google’s crypto tokens, Binance’s regulatory troubles, free NFTs and more — Here’s what happened in the world of crypto this past week
Popular on BI
- Electric two-wheeler sales grow by 24% in February 2024, Ola Electric leads with over 40% market share
- Gupshup launches Conversation Cloud, AI-powered tool for businesses
- Platinum Industries shares make market debut with over 33% premium
- Exicom Tele-Systems' shares debut with nearly 87% premium
- China retains 5% growth target for 2024 as economy struggles to shake off slowdown